project report on zensar pharma
TRANSCRIPT
-
8/3/2019 Project Report on Zensar Pharma
1/88
A SUMMER TRAINING PROJECT REPORT
ON
COMPARATIVE STUDY OF ZENSAR PHARMACEUTICALS
For the partial fulfillment of Master of Business Administration Program
UNDER THE GUIDANCE OF SUBMITTED BY :
Dr. Vinitendra Pratap Singh Mohammad Shairan
(HOD, MBA) MBA IIIrd Sem.
B.N. College of Engineering & Technology, Lucknow
(Affiliated to Gautam Buddh Technical University)
Session: 2011-2012
1
-
8/3/2019 Project Report on Zensar Pharma
2/88
TABLE OF CONTENT
ACKNOWLEDGEMENT
OBJECTIVES & SCOPE OF THE STUDY
PART- I
Introduction
Company Profile
Services/Products provided by the company
Introduction to the topic
Analysis of the topic
Part- II
Research Methadology
Findings
Graphs
Data Analysis
Limitations
Conclusions
Suggestions & Recommendations
Bibliography
Appendix
2
-
8/3/2019 Project Report on Zensar Pharma
3/88
ACKNOWLEDGEMENT
Like most endeavors, preparing this project was a collaborative effort. I owe a great debtto many individuals who helped me in successful completion of this project.
I would like to express my sincere gratitude to COMPANY NAME for giving me an
opportunity to complete my summer internship program in their esteemed organization.
I would not have completed this journey without the help, guidance and constant support
and co-operation of certain people who acted as guides and friends along the way, I would
like to express my deepest and sincere thanks to Dr. UPAMA Mishra ( Director , B.N.
College of Engineering & Technology) , Dr. Vinitendra Pratap Singh ( H.O.D. ,
M.B.A. Department), and for their invaluable guidance and help. The project could not
have been completed without their support and guidance.
In this connection I would like to express my gratitude to my parents and friends who
were constant source of inspiration during my summer training project report. At last I
thank to Almighty for giving me the power to complete this project successfully.
Mohammad Shairan
MBA IInd year
3
-
8/3/2019 Project Report on Zensar Pharma
4/88
OBJECTIVE OF STUDY
The key objectives of the Study are as follows:
To assess the build up in brand health of Zensar and the impact of the
communication to answer the questions
Is the advertising creating awareness and saliency for the brand?
Is advertising being noticed?
Is the message been picked up and comprehended?
Is the brand been integrated with the message? Is the brand communication created a favorable disposition for the
brand?
4
-
8/3/2019 Project Report on Zensar Pharma
5/88
COMPANY PROFILE
Ranbaxy, a leading name in pharma and healthcare has recently started a new
initiative in OTC drugs, with a focus to take advantage of the growing Rs
3000 crore OTC market in India. This new division is called Ranbaxy Global
Consumer Healthcare. Some of the erstwhile schedule H brands that have
been transferred to the OTC umbrella include Zensar, Pepfiz, Garlic Pearls
and Gesdyp. Zensar enjoys the flagship brand status among the switch
brands
The OTC brand of Zensar is being supported with a TV ad campaign
involving three creatives. Spends have been made on both C&S and
Doordarshan channels.
The Brand
Zensar is a comprehensive daily food supplement that has a balanced
combination of vitamins, minerals & ginseng.
Zensar was launched in 1989 as a prescription drug. The drug was promoted
as a product for energy enhancement, anti-stress and fighting fatigue, which
emanated from its key ingredient Ginseng.
However with the market dynamics changing with the rise of anti oxidant
category in prescriptions, prescription share of Zensar dropped through the
nineties. The brand however retained its volumes owing to consumers buying
it over the counter.
In 1999, it was taken off Schedule H of the drug controllers and became an
OTC product. Its currently classified as a food supplement.
5
-
8/3/2019 Project Report on Zensar Pharma
6/88
Key markets for Zensar include lower population strata towns and rural
markets as well.
The Category
The category, Adult Health Supplements, consists of Zensar, Becosule, other
vitamin capsules, Spirulina, Brahmi and Ashwagandha poppables from
Himalaya and other OTX drugs. (Drugs pushed by the Chemist, even if not
prescribed the doctor) While Zensar faces competion from these drugs, the
penetration of these brands is lowand occasional/ need based use is
predominant. Therefore the marketing task would be category creation,
rather than fighting for share from other players. Usage of these drugs is
usually linked to rejuvenation, energy enhancement, anti oxidant and anti
stress benefits. In terms of pricing, Becosule is a cheaper alternative to
Zensar. RGCH would now like to track the impact of the TV campaign and
other marketing activity on brand health and build up of associations with the
brand in consumer minds.
6
-
8/3/2019 Project Report on Zensar Pharma
7/88
INDIAN PHARMACEUTICAL COMPANY
The Indian pharmaceutical industry is a success story providing employment
for millions and ensuring that essential drugs at affordable prices are
available to the vast population of this sub-continent.
The Indian Pharmaceutical Industry today is in the front rank of Indias
science-based industries with wide ranging capabilities in the complex field
of drug manufacture and technology. A highly organized sector, the Indian
Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to
9 percent annually. It ranks very high in the third world, in terms of
technology, quality and range of medicines manufactured. From simple
headache pills to sophisticated antibiotics and complex cardiac compounds,
almost every type of medicine is now made indigenously.
The Indian Pharmaceutical sector is highly fragmented with more than
20,000 registered units. It has expanded drastically in the last two decades.
The leading 250 pharmaceutical companies control 70% of the market with
market leader holding nearly 7% of the market share. It is an extremely
fragmented market with severe price competition and government price
control.
The pharmaceutical industry in India meets around 70% of the country's
demand for bulk drugs, drug intermediates, pharmaceutical formulations,
chemicals, tablets, capsules, orals and injectibles. There are about 250 large
units and about 8000 Small Scale Units, which form the core of the
7
-
8/3/2019 Project Report on Zensar Pharma
8/88
pharmaceutical industry in India (including 5 Central Public Sector Units).
These units produce the complete range of pharmaceutical formulations, i.e.,
medicines ready for consumption by patients and about 350 bulk drugs, i.e.,
chemicals having therapeutic value and used for production of
pharmaceutical formulations
Following the de-licensing of the pharmaceutical industry, industrial
licensing for most of the drugs and pharmaceutical products has been done
away with. Manufacturers are free to produce any drug duly approved by the
Drug Control Authority. Technologically strong and totally self-reliant, the
pharmaceutical industry in India has low costs of production, low R&D
costs, innovative scientific manpower, strength of national laboratories and
an increasing balance of trade. The Pharmaceutical Industry, with its rich
scientific talents and research capabilities, supported by Intellectual Property
Protection regime is well set to take on the international market.
ADVANTAGES
Competent workforce:
India has a pool of personnel with high managerial and technical competence
as also skilled workforce. It has an educated work force and English is
commonly used. Professional services are easily available.
Cost-effective chemical synthesis: Its track record of development,
particularly in the area of improved cost-beneficial chemical synthesis for
various drug molecules is excellent. It provides a wide variety of bulk drugs
and exports sophisticated bulk drugs.
8
-
8/3/2019 Project Report on Zensar Pharma
9/88
Legal & Financial Framework: India has a 53 year old democracy and
hence has a solid legal framework and strong financial markets. There is
already an established international industry and business community.
Information & Technology: It has a good network of world-class
educational institutions and established strengths in Information Technology.
Globalisation: The country is committed to a free market economy and
globalization. Above all, it has a 70 million middle class market, which is
continuously growing.
Consolidation: For the first time in many years, the international
pharmaceutical industry is finding great opportunities in India. The process
of consolidation, which has become a generalized phenomenon in the world
pharmaceutical industry, has started taking place in India
THE GROWTH SCENARIO
India's US$ 3.1 billion pharmaceutical industry is growing at the rate of 14
percent per year. It is one of the largest and most advanced among the
developing countries.
Over 20,000 registered pharmaceutical manufacturers exist in the country.
The domestic pharmaceuticals industry output is expected to exceed Rs260
billion in the financial year 2002, which accounts for merely 1.3% of the
global pharmaceutical sector. Of this, bulk drugs will account for Rs 54 bn
9
-
8/3/2019 Project Report on Zensar Pharma
10/88
(21%) and formulations, the remaining Rs 210 bn (79%). In financial year
2001, imports were Rs 20 bn while exports were Rs87 bn.
STEPS TO STRENGTHEN THE INDUSTRY
Indian companies need to attain the right product-mix for sustained future
growth. Core competencies will play an important role in determining the
future of many Indian pharmaceutical companies in the post product-patent
regime after 2005. Indian companies, in an effort to consolidate their
position, will have to increasingly look at merger and acquisition options of
either companies or products. This would help them to offset loss of new
product options, improve their R&D efforts and improve distribution to
penetrate markets.
Research and development has always taken the back seat amongst Indian
pharmaceutical companies. In order to stay competitive in the future, Indian
companies will have to refocus and invest heavily in R&D.
The Indian pharmaceutical industry also needs to take advantage of the
recent advances in biotechnology and information technology. The future of
the industry will be determined by how well it markets its products to several
regions and distributes risks, its forward and backward integration
capabilities, its R&D, its consolidation through mergers and acquisitions, co-
marketing and licensing agreements
Current demand in the Indian pharmaceutical sector stands at about $4 to $5
billion, and is forecast to increase at an annual rate of 15 - 20% in the future.
Nevertheless, average per capita expenditure on pharmaceuticals in India is
10
-
8/3/2019 Project Report on Zensar Pharma
11/88
only $3 -- compared to $412 in Japan, $222 in Germany and $191 in the US.
This is due in part to the prevalence of alternative healing methods in India,
such as ayurvedic medicine and homeopathy, but also because prices for
drugs have been kept artificially low by the Indian government. In fact,
India's pharmaceutical industry is one of the most highly regulated industries
in the country. Price controls have a strong effect on profitability in the
industry, and weak patent protection poses a long-term threat to investment
in India's drug market. Foreign firms also find it difficult to operate in India
due to arbitrary Bureau of Industrial Cost and Pricing (BICP) pricing
changes, arbitrary local FDA decisions, high import duties (about 42%) and
complex import procedures.
However, while the pharmaceutical sector in India wills most likely stay
regulated in the short term, there are plans for reform. The sheer size and
growth of India's domestic pharmaceutical industry is making it increasingly
difficult for the government to regulate prices for every single firm, and
pressure from the World Trade Organization is also speeding up discussions
within the national government to improve patent protection. As a result,
foreign pharmaceutical firms can expect improved market opportunities in
India's enormous drug market over next several years
11
-
8/3/2019 Project Report on Zensar Pharma
12/88
MARKET STRUCTURE OF THE INDIAN PHARMACEUTICAL
INDUSTRY
The Indian pharmaceutical industry is highly fragmented -- there are now
more than 20,000 domestic manufacturers of end-use pharmaceuticals,
particularly because of the industry's low capital requirement and the lack of
product patents. Only about 300 of these are in the organized sector. This
structure causes intense competition, especially in the bulk drug markets,
with profitability falling as demand expands.
For value purposes, drugs in India are generally classified into two categories
-- bulk drugs and formulations. Due to India's low overhead costs, bulk drugs
comprise the largest sector in the country's pharmaceutical market. Indias
bulk drug sector also makes up about 6% of the international bulk drug
market. Drug intermediates are used as raw materials for the production of
bulk drugs, which are either sold directly or retained by companies for the
production of formulations. Formulations can be subdivided into generic
drugs and branded or "ethical" drugs, the latter of which are made under
process patent and sold under a separate brand name. Expected short-term
growth for the two types of drugs has been 20% for bulk drugs and 15% for
formulations.
The import of finished pharmaceuticals is almost negligible, and confined to
very specific types like anti-cancer drugs. In 1994, the import of drugs,
pharmaceuticals and intermediates was estimated at $450 million, and
included the following: antibiotics, penicillin and its salts, erythromycin and
its preparations, vitamins and provitamins, vaccines (polio, human and
12
-
8/3/2019 Project Report on Zensar Pharma
13/88
veterinary), preparations containing insulin, caustic and other hormones, and
tetracycline and its preparations.
Essential drugs comprised of antibiotics, antibacterial, anti-TB, anti-parasitic,
and cardiovascular constitute a major portion of turnover of the industry.
Indian companies dominate this class of drugs with a market share of 71%.
Multinational companies are reluctant to enter these markets as most of them
are under government price controls.
13
-
8/3/2019 Project Report on Zensar Pharma
14/88
ABOUT THE ZENSAR
Zensar Technologies (Zensar) is a globally renowned software services company that
specializes in providing a complete range ofSoftware Services and Solutions. Zensar is
ranked amongst India's Top 20 Software Services Companiesby National Association of
Software and Services Companies (NASSCOM) and is also recognized by the
Department of Scientific and Industrial Research (DSIR) for its robust in-house Research
and Development practices and an acknowledged leader in Innovation. The Software
services range from the traditional to the transformational Enterprise Product
Implementation and Hosting, Business Intelligence and Data Warehousing, Collaboration
and Knowledge Management Services, Business Process Outsourcing and Optimization,
Remote Infrastructure Management and Testing, and the entire range of Software
Application Planning, Portfolio Building, Development, Migration and Support. Zensar is
the world's first enterprise-wide SEI CMM Level 5 Company and enjoys a strong
presence in the United States, Europe, Africa, Middle East and Asia-Pacific regions.To
service Global Customers, Zensar has Delivery Centers in Pune and Hyderabad in India,
China, Japan and the UK. With 6000+ associates, 400+ customers and 14 nationalities
operating in more than 20 global locations, Zensar helps transform Global Corporations.
14
-
8/3/2019 Project Report on Zensar Pharma
15/88
Zensar encourages challenging of opinion, of mindsets and a young and
vibrant culture of innovation and experimentation. It consciously focuses on
building diversity into the system whether it is of gender, region, nationality,
background, learning or education, and then in creating a framework for a
confluence of these different ideas, cultures and experiences to make an
authentic global organisation that delivers value to its customers. At Zensar
individual thinking, creativity, innovation and flexibility are celebrated and
through that enormous diversity seeps in a 'world culture' for Zensar to
become true transformation partners to global corporations driven by a set of
core organisational values - that being the only place for homogeneity!
Using the Global Delivery Model in integrating global talent including
customer capabilities, embedding frameworks for service delivery, and by
creating the necessary go-to-market front ends, Zensar demonstrates business
value for its customers! This enables a true customer proximal model by
requirements being captured by a consultant at their end with localized and
business specific capabilities and the luxury of global sourcing and
24X7X365 support and disaggregated software development that leverages
talent across nations.
ZENSAR VALUABLE CLIENTS
Towards creating value to its customers business, Zensar has built and
consolidated a comprehensive portfolio of services in IT and BPO, lending awide range of benefits from cost arbitrage, to unmatched quality,
differentiated value to a holistic strategic partnership with its customers; and
further lending a significant advantage by offering models to customers that
15
-
8/3/2019 Project Report on Zensar Pharma
16/88
best suit their business needs traversing the context areas down to the core
focus areas of the customer.
Zensar enjoys enduring relationships with global leaders like Cisco,
Assurant, Danaher Corporation, Electronics Arts, iSelect and Logitech,
among several others. Zensar's customers are spread across various industry
segments like Manufacturing, Retail, Banking and Insurance, High-Tech
manufacturing and Connected Services. Zensar has also forged strategic
technology partnerships with global technology leaders such as IBM,
Microsoft, Sun Microsystems and Oracle. These partnerships enable Zensar
to leverage its core competencies, ensuring comprehensive and state-of-the-
art business solutions to its customers.
ZENSAL EXPERTISE
The Company offers industry and business consulting with industry focused
teams in Retail, Manufacturing, Banking, Insurance, Energy and Utilities,
Media and Connected Services (Government, Education and Healthcare),
bringing in best practices culled from individual and combined experiences.
Zensar's decision enabling services lend velocity to the customer's business
by process and technology consulting that help corporations make better
decisions. The services include enablers like business intelligence and data
warehousing, content and collaboration management, and knowledge
management.
The Business Process Outsourcing and Optimisation (BPO2) based
services of Zensar as the name suggests involves process execution and
optimisation to help businesses perform at optimum levels by making
16
http://iselect.com.au/http://iselect.com.au/ -
8/3/2019 Project Report on Zensar Pharma
17/88
continuous improvements possible. The services in this space span from
accounts payable, receivables, telesales, helpdesk support, to Knowledge
Process Outsourcing on the higher end.
OurIT Enabling Services help companies design, develop, implement and
test applications whether packaged or even custom-built to enable their
business processes. Zensar has a strong engagement with Oracle being their
platinum partner with a 1300+ consultants team; and in the SAP space
offering focused templatised solutions in key verticals of dairy, textile,
pharma, manufacturing and IT/operations and being the largest partner in
certain key segments and markets. Our teams bring a strong blend of
functional business skills and technology or package-specific expertise to
help make swift implementations possible with minimal risk rendering
maximum value.
Zensar's IT Support Services help companies focus on their core of aligning
IT to business needs while letting us take care of the operational
maintenance, fixes and day-to-day support of their applications and
technology infrastructure.
17
-
8/3/2019 Project Report on Zensar Pharma
18/88
Our Vision
Transformation partners to global corporations.
Our Values
Customer Sovereignty
Our customers are the reason for our existence. We anticipate their needs and
endeavor to meet and surpass their expectations.
Passion For Excellence
We strive to attain individual and team excellence through a spirit of
continuous learning, lofty standards, new ideals and a commitment to high
levels of achievement.
Continuous Innovation
We aspire to seek and create a 'new way.' We will continuously reengineer
our processes and mindsets and encourage individual creativity and
improvisation in all our actions.
Transparency and Integrity
We will nurture a culture of spontaneity and mutual trust. Impeccable ethics
and morals will be the cornerstone of all our interactions and relationships.
People Orientation
We will accord empathy, respect and dignity to every Zensarian. We will
create an environment where every committed and capable member of the
18
-
8/3/2019 Project Report on Zensar Pharma
19/88
organization is given ample rewards and opportunities for growth.
Social Responsibility
We will recognize, abide by and add value to the social environment, while
embracing our responsibilities as a good corporate citizen in every country
we operate.
GLOBAL DELIVERY PLATFORM
Zensars Global Delivery Platform (GDP) provides collaborative solution
delivery across shores and enterprises seamlessly. The Platform combines
mature off-shoring processes, which emulates industry best practices and a
community of intellect across the globe that spans multiple business domains
using Zensars proprietary Solution Blueprint ( SBP) . SBP enables Zensars
global delivery platform where capabilities of software professionals across
geographies can be leveraged without physically bringing them under one
roof. Using SBP these talented professionals will essentially focuses on
designing whereas SBP would handle the routine software code to generation
activity.
The global delivery platform thus significantly reduces people dependence
and technology bondage to deliver agile, flexible and future-proof solutions
on demand.
Zensars SBP enabled, unique GDM is virtual, and defies the traditional need
for brick and mortar structures to service customers.
These solutions are provided to customers on an Opti-Shore Delivery
Model, often tailored to suit individual customer requirements. The GDP
provides our customers with flexibility, a choice of differentiated services,
access to a global expertise pool, new business channels and provides
software that is standardized and built to last. The GDP also provides access
19
-
8/3/2019 Project Report on Zensar Pharma
20/88
to world class business and application modeling using a distributed and
collaboration environment enabling Zensar to seamlessly deliver IT-Enabled
Services and Solutions from global locations
20
-
8/3/2019 Project Report on Zensar Pharma
21/88
ACHIEVEMENTS
Zensar is committed to meet customers' needs and expectations by
delivering competitive IT and Business Process Outsourcing
solutions. This sentiment is evident from our continuous
perseverance to accredit ourselves with globally recognised
industry standards and the awards we are bestowed with by various
global institutions
Golden Peacock Award for CSR - 2011
Zensar Technologies has been selected as the winner of Golden Peacock
Award for Corporate Social Responsibility for the year 2011 by the Awards
Jury, under the Chairmanship of Justice P N Bhagwati, former Chief Justice
of India and Member, UN Human Rights Commission. The Golden Peacock
Awards are recognized worldwide as the hallmark of corporate excellence
because of their independence, integrity, transparency and thorough and open
application process. The Golden Peacock is a very prestigious and well-
known award in the field of CSR in India.
International Association of Outsourcing Professionals
Zensar Technologies was recognized by the International Association of
Outsourcing Professionals (IAOP) among the Top 100 Global OutsourcingCompanies - 2008, 2009, 2010, and 2011. Zensar was also ranked in several
group categories - Best 20 Leaders by Industry Focus Financial Services,
Retail, Manufacturing and Industry Specific Services IAOP 2011.
21
-
8/3/2019 Project Report on Zensar Pharma
22/88
Named in Global Services 100 list - 2010
Zensar has been recognized as an organization that has reacted well to
changing demands and markets via their career development strategies and
has implemented change management initiatives at its best
Ranked among top 20 IT exporters in India by NASSCOM
Zensar Technologies has been ranked among the top 20 IT Services
Exporters for the year 2009-10 by the National Association of Software andServices Companies (NASSCOM) of India
Investment in People Award 2010
Zensar Technologies was awarded the Asia Responsible Entrepreneurship
Awards (AREA) Investment in People Award 2010 in New Delhi on the
20th of November, 2010 by Enterprise Asia, a non-governmental
organization in pursuit of entrepreneurship development across the region.
Founded by entrepreneurs for entrepreneurs, the organization is supported by
a panel of prominent industry and government leaders who truly believe in
the mission of championing entrepreneurship in Asia. AREA recognizes and
honors Asian Businesses for championing sustainable and responsible
entrepreneurship
22
-
8/3/2019 Project Report on Zensar Pharma
23/88
CNBC TV 18 International Trade Award-2007, 2008, 2009
In appreciation of its outstanding contribution to Indian trade CNBC-TV 18
has honored Zensar with The Exporter of the Year Award for three years
continuously for wealth creation in India's international trade community
Winner of FICCI's CSR Special Jury Commendation Award
Zensar has been awarded the 'Special Jury Commendation' Award by the
President of India, Dr. A.P.J Abdul Kalam for the outstanding commitment
and contribution to Nation Building through CSR efforts.
Employer Branding Awards 2007-2008
Zensar has been recognized as an organization that has reacted well to
changing demands and markets via their career development strategies and
has implemented change management initiatives at its best
Recognised by the BBB
Zensar has been recognised by the BBB and has received the BBB online
reliability seal. Zensar is now part of core group of businesses that support
ethical business practices and integrity in the market place
Trailblazer of the Year Award for Best HR Practices-2006
In recognition of the outstanding contributions and achievements,
particularly in the field of Human Resource & Development, the National
HRD Network honored us with the Trailblazer of the Year Award from
NHRD for Best HR Practices for 2006Zensar has also been recognized for its
23
-
8/3/2019 Project Report on Zensar Pharma
24/88
unique HR practices by the Madhya Pradesh government which recently
conferred the Golden Edge Award for Best HR practices for 2006
Corporate Governance Business Award-2006
For its unique contribution to the society, Zensar won the Corporate
Governance Business for Social Responsibility Award for 2006, which was
presented by Bombay Stock Exchange in association with Times Now
24
-
8/3/2019 Project Report on Zensar Pharma
25/88
SERVICES OFFER
IT Process Consulting
Why do 2 out of 3 Software Projects (66%) fail to deliver within Time, Cost
and Quality parameters?
How will streamlining processes of IT infrastructure and service
management achieve cost benefits; at the same time improve SLA
compliance too?
How to identify and alleviate risk and regulatory non-compliance using
industry accepted Governance framework?
Why Business-IT alignment is still the CIOs top priority?
These are some of the acute problems faced by organizations today, with one
common thread binding them all - immature process. It is the prime cause
for inefficiencies and ineffectiveness. It leads to duplication of work,
inconsistency, lack of common goal, inability to scale up, silo focus, lack of
measurement and improvement and many more.
We, at Zensars ITPC (IT Process Consulting) practice, help you to simplify,
optimize and thus improve maturity of the underlying processes. Our focus is
on
- delivering solutions targeted at enhancing productivity
- improve service and project delivery
- cost optimization
- alignment with industry recognized frameworks/standards using process
solutions
ITPC helps you to achieve the above challenges. This is accomplished using
our proven methodology ProZEN across the areas of IT Service Management
25
-
8/3/2019 Project Report on Zensar Pharma
26/88
(ITSM), Software Engineering and Quality Assurance, Process Optimization
and IT Governance.
SERVICES OFFERING
Source:www.zensar.com
IT Service Management: To manage IT services and systems
Software Engineering: For maturity of software development and
maintenance
Process Optimization: To achieve best out of your process
IT Governance: To gain efficiency, control, compliance and business
alignment
26
-
8/3/2019 Project Report on Zensar Pharma
27/88
BEST PRACTICES
Best practices we use are -
IT Infrastructure Library (ITIL) by OGC
Capability Maturity Model Integrated (CMMI) by SEI
People Capability Maturity Model (PCMM) by SEI
Microsoft Operations Framework (MOF) by Microsoft
Control Objective for IT (COBIT) by ISACA
PMBOK by PMI
Six Sigma and Lean
ISO 20000, 27000 and 38500
Business Process Management Suite by OMG
SCAMPI and Goal-Question-Indicator-Measurement by SEI
27
-
8/3/2019 Project Report on Zensar Pharma
28/88
Source:www.zensar.com
28
-
8/3/2019 Project Report on Zensar Pharma
29/88
MARKET METHODOLOGY:
Our Methodology ProZEN is the cornerstone for being able to deliver a
consistent experience to all our customers. It is flexible to suit your need.
Source:www.zensar.com
ProZEN is a structured yet flexible methodology at each stage, meaning you
can engage us for one or all of the distinct services depending on your needs.
What makes ProZEN unique is the detailed attention it provides for an end to
end process solution while maintaining / retaining customer centricity.
29
-
8/3/2019 Project Report on Zensar Pharma
30/88
VALUE POSITION
Holistic, more complete view
Our "Multimodal" process improvement provides more flexibility and
agility. We can leverage the differentiating features of each model
Efficiency
Effective & efficient execution using rigor of world class Project
Management built in ProZEN methodology
Effectiveness
Our Assessments, coupled with benefit realization analysis help you
identify the low hanging fruits and long term actions that are tightly
linked with business needs and priorities
Acceleration
Leveraging our own IP and considering your existing initiatives give
you quicker turn around.
Business Benefit RealizationOur structured approach for Organization Change Management speeds
up the adoption rate of the new process and ensures business gain
Cost Advantage
We leverage our offshore team to provide you virtual consultancy very
cost effectively.
Our Consultants
Depth and breadth of our consulting team will provide unsurpassed value to
you. We have qualified consultants certified in - ITIL Managers (EXIN),
CISA (ISACA), 6 Sigma Black Belts, PMP, IDS-Scheer ARIS, SCAMPI(B)
Lead Appraiser and many more.
30
-
8/3/2019 Project Report on Zensar Pharma
31/88
Impact Sourcing
Despite the uncertain economic outlook and cash flow pressure, Zensar
believes that the current market conditions can provide new opportunities for
organizations that are already outsourcing, or planning to outsource, their
processes and function to reap significant financial and non-financial benefits
in the immediate future. Impact Sourcing is a unique methodology that will
help drive high performance in the near and long term to organizations.
Impact Sourcing assures 10 % cost savings within 10 months by deploying a
best-of-breed COBIT framework & ITIL methodologies to generate a future
roadmap tailored for organizations to meet their optimization needs. We can
bring rigour and discipline to existing business functions and drive value by
fixing distressed and winding processes reducing risk in complex contracts,
and forming partnerships. We help our clients to formulate and implement
strategies, reduce costs, increase efficiency, drive innovation and expand into
new markets with immediate effect to costs
Benefits
Strong lineage in helping organizations create a comprehensive
optimization plan
Phased approach helps organizations identify the 'cost culprits'
Best practices helping organizations benchmark with the industry
Domain expertise, technology and process capabilities coupled with
strong focus on quality deliverables provide added benefits to the
customers in their optimization initiatives.
Information Architecture Services
31
-
8/3/2019 Project Report on Zensar Pharma
32/88
IA is the art and science of organizing and labeling websites, intranets,
online communities and software to support usability The Information
Architecture Institute
At Zensars IA CoE we constantly strive to ensure the right blend of this art
and science is achieved every time we deliver our IA services which allow
users to achieve their goals efficiently and effectively. Our Usability and IA
services work in unison to provide an unmatched level of user comfort and
content positioning by leveraging the rich experience of our IA architects and
Knowledge Strategists.
IA as we perceive is about the approach/methodology that effectively
structures the unstructured
The IA Practice focuses on the following Service lines:
Business case development
Business Solution Map
Information needs analysis
Information structure and page layouts Creating controlled vocabularies and metadata
Search engine optimization
Enhancing content management systems
Best Fit Technology Implementation-Information Storage, Access &
Delivery Platform
SOFTWARE SERVICES
32
-
8/3/2019 Project Report on Zensar Pharma
33/88
We help enterprises expand their businesses by Custom Application
development and implementation services that are capable of performing
across multiple platforms and infrastructures. Cost-effectiveness and strong
delivery capabilities in Agile and Waterfall Methodologies are at the focus of
our application development and maintenance strategy. Our
matured application development services encompass all the phases of
Software Development Life Cycle (SDLC), starting from translating business
needs into project requirements through implementation and post-production
user support. With a rich experience of providing cost effective and quality
custom application development services and solutions capable of consistent
performance, Zensar can provide rapid adaptation- with minimal
interruptions in the current processes and has worked with a Fortune 500
clientele worldwide.
33
-
8/3/2019 Project Report on Zensar Pharma
34/88
Value Proposition
Use of home grown Solution BluePrint (SBP)framework during various
phases of application development
Use of Global Delivery Model
Focus on using re-usable components and tools reducing cycle time
and costs
Alliances with reputed technology firms (Microsoft GOLD certified
partner, Oracle Certified partner)
Knowledge acquisition and retention using CMMI processes
Application Support & Maintenance
In the software lifecycle, nearly 70% of the cost goes into Application
Support & Maintenance activities. Research suggests that large enterprises
spend an average of 73% of their IT budget on Application Maintenance of
existing system. Clearly, Application Management presents high potential
for cost savings in global enterprises.
Zensar's expertise in Application support and maintenance has seen a long
list of partnerships with fortune 500 customers for more than a decade,
Zensar offers a cost effective solution to customers through
Focus on performance measures and continuous improvement besides
Service Level Agreements (SLAs)
Timely resolution of issues and root cause analysis of each issue
Established support matrix offering Help Desk services and
34
http://www.solution-blueprint.com/http://www.solution-blueprint.com/ -
8/3/2019 Project Report on Zensar Pharma
35/88
Multi-level maintenance process using a Corrective, Preventive,
Adaptive & Perfective approach
Best Practices
Continuous improvement in application support and maintenance
services with objective of lowering Total Cost of Ownership (TCO)
Established practice focusing on defining / improving processes
Feedback of lessons learned from projects to practice for wider
implementation
Generating knowledge repository of issues / resolution for futurereferences.
Value Proposition
Experience in supporting mission critical / business critical application
for fortune 500 customers
Decade long relationship with most of our customers
Single window for providing application maintenance and support
with infrastructure management
Providing continuous improvement against industry standards and
benchmark
Binding SLA framework with Critical Service Level (CSL) and
Quality Process Processes in line with ISO 9000 Standards and the SEI-CMMI
framework
35
-
8/3/2019 Project Report on Zensar Pharma
36/88
User Experience Solutions
Low conversion rates on your ecommerce site?
High transaction failures on your net banking site?
Poor user experience could be the barrier to your websites success
Click the button below for a FREE Assessment of your site
Zensars User Experience team helps you create positive and
impactful experiences for your users. We design simple and effective
interfaces for software applications, products, websites or mobiles
Best Practices
Some best practices we ensure in our approach to any project
Involve end users in the design process, to the extent possible
Use lo-fidelity prototyping extensively to set the tone for the UI
requirements
Encourage iterative mode of prototyping to get it right!
Our HTML aligns with W3C priority 1 accessibility guidelines
Use informal methods of usability testing to give users a comfort
feeling
Value Proposition
User adoption is at highest levels - successful products/applications
Supporting mission critical / business critical application for fortune500 customers
Providing continuous improvement against industry standards and
benchmark
36
-
8/3/2019 Project Report on Zensar Pharma
37/88
Application Migration & Modernization
Studies show that over 70% applications of the world are still on
Mainframe and Legacy systems, and most businesses are in a
desperate need to modernize and upgrade their IT applications
environment. Zensar's Application Migration, Re-engineering &
Modernization services help customers to modernize and migrate from
older platforms to newer ones with minimum risks. Zensar has
effectively modernized legacy applications by improving operational
efficiency, reducing the cost of doing business and improving
information assets. We have a proven track record of successfully
modernizing large mission-critical mainframe and legacy system
projects for Fortune 500 clients.
Embedded Software:
Embedded Software in Zensar is focused on design and development
in the areas of computing systems(PC's and Servers), Networking and
Datacom, Peripherals, Storage devices and systems, Mobile and
multimedia applications & systems. We also specialize in
development of automated testing tools for hardware and software
products and systems in the systems and embedded software space.
Completing the entire ecosystem of embedded software services there
is a verification and validation of products and systems for
specification conformance, performance and inter-operability. Our
37
-
8/3/2019 Project Report on Zensar Pharma
38/88
host of embedded software services applies to Product
Conceptualization and Development, Design Verification, Mass
Production and Maintenance.
Product Engineering
Zensar has a template based approach to implement processes in rapid
product life cycles. Innovations likeSolution BluePrint help in
improving productivity, creating value and leading to a model driven
approach to software product engineering services. Zensar during its
long experience in providing software product engineering services
has worked closely with ISVs like Informix, Microsoft and Fujitsu.
With development experience in multiple products and components
ranging from back end retailing solution, story creation product,
middleware components and drivers for database, Zensar also has
implementation experience in creating a language independent -
platform independent - database independent programming library for
its customers. With product development life cycle being highly
changeable and time to market increasingly becoming shorter,
mechanisms like agile development and the iterative models are
essential component in software product engineering services at
Zensar. This learning has also led to advanced services around
technology refresh and on-demand models (SaaS).
With our metrics driven approach, we can set performance targets,
measure the performance and consistently show improvement. The
extended team approach gives complete visibility and control to the
customer. Our methodology involves a phased approach:]
38
http://www.solution-blueprint.com/http://www.solution-blueprint.com/ -
8/3/2019 Project Report on Zensar Pharma
39/88
Independent Testing Services
Dont let cost of poor quality burn your margins. Adopt independent
testing!
Software testing plays a pivotal role in program assurance. The impact
of the cost of poor quality is experienced only after systems go into
production and is rarely considered before or during program
implementation.
Software testing has evolved into a very mature discipline and is a
vital business-enabling function within any organization undertaking
critical transformation programs. Software testing plays a crucial role
in program assurance activities, helps achieve lean IT operations,
provides business enablement and also control the Total Cost of
Ownership (TCO).
Zensar has setup a Testing Centre of Excellence to drive the adoption
of a disciplined approach towards testing from a quality control and
assurance perspective. Our processes and frameworks assist in the
extremely efficient conduct of software testing. Enabled by
organization level baselines and best practices, Zensars testing
practice focuses on end user needs. Our test lab services incubate new
solutions to meet emerging industry trends and with a plethora of both
licensed and open source tools, we are able to suggest the most
appropriate solution bases on customer needs.
39
-
8/3/2019 Project Report on Zensar Pharma
40/88
Service Offerings
Methodology
Our investment in building reusable test assets translates into immediate
benefits to the customer, in terms of increased efficiency and shorter time to
market. Our ready made test assets in Oracle Applications, Insurance, Retail
domains provide head start in testing projects.
Standardized test and defect management processes are followed
Reusable test artifacts are created and managed
Improvements are driven by metrics data gathering and analysis
Best Practices
Our test lab is involved in tool based technology development and has
indigenously developed the following tools/frameworks:
40
-
8/3/2019 Project Report on Zensar Pharma
41/88
Robust, extensible Test Automation Framework (450 reusable
functional libraries)
Pre-Processor to reduce automation tool licenses for script
development
Tzen - Zensar's Test Management Tool (Platform independent, Cost
effective, Fully customizable, Extendible, Integration possibilities with
Open Source Testing Tool Mantis)
Risk Based Testing methodology
Automated test case generation from use cases using Zensars SBP
(Solution Blueprint)
Value Proposition
Ready availability of certified testing practitioners for deployment with
customer projects
State of the art test lab with licensed (IBM, HP etc), Open Source
(OpenSTA, Jameleon) tools
Ready made Test automation framework supporting Oracle Apps,
Java, .Net and Web applications for a head start
IP solutions 'Automation Preprocessor' for immediate implementation
in test automation without application software being available
Testing team with domain knowledge in Financial and Insurance
Services, Retail, Manufacturing, Energy and Utilities, Shipping,Logistics and Oracle Applications
Zensar's own test management tool (TZen) for productivity
improvements
41
-
8/3/2019 Project Report on Zensar Pharma
42/88
Insurance
In today's scenario, Insurers face issues like globalization, growing demand
for web based services, regulatory demands, security threats and outsourcing.
We understand the needs of the industry and offer Innovative Solutions
which are unique, optimal and customer focused. Through a unique blend of
domain knowledge, technology and robust processes we have successfully
provided solutions to our leading Insurance Customers who faced challenges
like
Demanding business need for new, innovative applications in the
shortest possible time
Striking balance between new technology adoption and the legacy
environments
Long term plan for Application Integration, re-engineering and
retirement
Application and infrastructure maintenance
Availability of skilled resources Managing dynamic regulatory compliances in the legacy environment
42
-
8/3/2019 Project Report on Zensar Pharma
43/88
Service Offerings for Insurance
We provide end-to-end IT services and solutions helping insurers in achieve
operational excellence, exceed customer expectations, faster time-to-market,
while driving their top-line revenue growth.
Application
Development & Maintenance Services
We offer cost effective solutions using our dual shore, onshore, near shore,
offshore delivery methodologies. Backed by our strong processes for
Application Support, Development and Legacy Transformation, our core
competencies lie in the functional areas of
New Business and Underwriting Systems
Policy Administration and Claims Processing
Agency Management Systems
Insurance Distribution Channel Management
Web enablement/Development of websites
Development of front-end applications to Legacy Systems
43
-
8/3/2019 Project Report on Zensar Pharma
44/88
Finance and Accounting
Regulatory Compliance
Testing Services
We provide end-to-end testing services to the Insurance Industry to ensure
faster time-to-market by utilizing our test assets like library of test cases for
the Insurance Industry, automation of test scenarios, and host of in-house
developed tools. Our suites of testing services include functional testing,
operational acceptance testing, security testing and performance testing.
Consultancy Services
We provide consultancy in the areas of Enterprise Architecture, Design
Architecture, Data Migration, Usability Engineering for B2B/B2C websites,
Offshore Advisory services, Packaged Solution and Process implementation
services. We also provide IT staff augmentation services to Insurers who
look for specific skills and profiles.
Business Intelligence
Having provided end-to-end BI solutions for several Global Insurance
Organizations, we have been able to develop the expertise required to help
Insurance companies achieve performance excellence with custom-made BI
Insurance Solutions. Our solutions encompass every critical function that
needs monitoring to improve the overall productivity and profitability of an
Insurance Organization. These industry centric solutions, along with our
Strategic Business Intelligence Framework provide the BI Excellence, which
is the key to Enterprise Performance Management. Zensar's Business
44
-
8/3/2019 Project Report on Zensar Pharma
45/88
Intelligence and Data Warehousing Solutions for the Insurance Industry
include Channel & Product Profitability, Underwriting and Claims
Intelligence, Broker and Delegated Billing Entities Intelligence, Finance,
Sales Force Performance Management and Customer Service Analytics
Banking
Banking and Financial Services Practice at Zensar is built on the strength of
four core competencies - Domain, Process, Technology and Innovation. The
practice is boosted by a myriad of activities like industry research and trends,
tools evaluation, continuous process optimization, innovation leading to
intellectual property, publishing white papers and capturing experiences in
the form of best practices and case studies.
Zensar's Banking and Financial Services Practice addresses the needs of
clients by leveraging its rich industry experience and deep technology
expertise. Our highly qualified team engages with clients to help them
implement sustainable business strategies while maintaining cost efficiencies
and thereby, gain competitive advantage in their marketplaces. Through a
network of alliances and partnerships, we provide true end-to-end business
transformation services to our clients.
Service Offerings in Banking
The bouquet of our service offerings cut across various horizontals like
application development, modernization and migrations, support and
maintenance and high-end consulting in major industry segments including
Retail Banking, Private Banking and Wealth Management, Capital Markets,
Compliance and Risk Management
45
-
8/3/2019 Project Report on Zensar Pharma
46/88
Innovative Framework - Solution Blue-Print (SBP)
SBP is an in-house developed technology framework that facilitates and
simplifies the development and maintenance of software thus reducing costs
and improving productivity through process automation
Significant ROI is realized by the utilization and reuse of pre-built
models from the Enterprise Repository
Solution BluePrint are platform agnostic, thus enabling the
development of multi-platform deployable solutions whenever needed
Global Distributed Delivery Model
Process innovation fueled by an impeccable track record for
providing solutions to both public sector and the private sector globally
has resulted in Zensar's Global Delivery Platform (GDP) and thus
providing for collaborative solution delivery across shores and
46
-
8/3/2019 Project Report on Zensar Pharma
47/88
entities seamlessly. This also enables Zensar to provide solutions to
customer on "Opti-shore delivery model" across multiple
geographies, often tailored to suit individual customer
requirements.
Lower cost of implementation /maintenance, faster time-to-market,
ready pool of trained and qualified professionals, and flexible staffing
with increased agility for ramp-up/down
Functionality Readiness Matrix
Overview
Helps client achieve set targets of time-to-Market for the
Product/Service offering
Facilitates risk based testing and gives client optimum Quality in given
time
Assurance of reliable application roll out mitigating risk to Brand
Image and Business (Revenue) Opportunity without compromising
Quality
Strike balance between Time and Quality with optimum cost
Identification of Functional Reliability and Business Risks
Goal/Target setting for mitigating identified risks, test completeness
and defect resolution
Continuous data feeds from external processes like Test Status
Reports, Traceability Matrix, Defect Status reports, Project
Management Plans etc for decision making (Dynamic and periodical)
Providing Client and Project management with a "big picture" view of
status
47
-
8/3/2019 Project Report on Zensar Pharma
48/88
Energy and Utilities
Energy and Utilities (E & U) practice of Zensar possesses deep domain
expertise and exposure to Global Utility markets backed by 15 years of
hands on experience in the Industry's core technologies. E & U practice has
participated in the regulation and deregulation journey of the energy markets
and is actively assisting customers in achieving their goals and objectives.
E & U practice has acquired, expertise in the entire value chain of Energy &
Utilities industry's upstream, mid-stream, down-stream sectors and back
office operations with cumulative experience of 150+ projects and
over15000+ person years.
Upstream
Transmission Outage and Generation Availability,
Asset Management and Maintenance
Inventory Control
Fuel management
Midstream
Network Analysis, MIMS
Balancing Mechanism
Integrated Energy Management BETTA
Mains Risk Priority Management
SCADA GIS
Downstream
Emergency Meter Work
48
-
8/3/2019 Project Report on Zensar Pharma
49/88
Job Issue System
Demand Derivation system
Field Force Device Replacement,
Connections work management & AMR,
Market Intelligence & Provision of Information
Back Office Operations
Knowledge Management
Enterprise Collaboration
EUC Applications Infrastructure Management
ERP
Service Offerings
Energy and Utilities practice has been providing the following services in
Analyzing and implementing regulatory and de regulatory changes, Legacy
Systems, Business process alignment and IT system improvements, Rapid
Application development to drive business benefits, Regulatory reporting ,
Program Assurance, Performance management, Application separation, and
consolidation due to deregulation or mergers and Acquisition, System
Integration and Green IT services We specialize in Advanced Meter
Management and Energy trading with our framework based solution, for
prototype and POC based implementation. We have local market experts as
partners for European and Indian markets.
49
-
8/3/2019 Project Report on Zensar Pharma
50/88
Best Practices
Market Study: Understanding of the history, back ground , impacts and
future of regulations and de-regulations in UK. Participated in handling
innumerous IT system impacts due to regulation and de-regulations
FOMSA Exit (Front office system separation)
SOMSA Exit (System Operation Systems separation)
Separation of IDNs and Interface building (Black water Program)
Connection unbundling
Regulatory reporting (Market Information provisioning projects)
Participation in RGTA / BETTA / TMA programs implementation.
Value Proposition
50
-
8/3/2019 Project Report on Zensar Pharma
51/88
Framework based development for Energy Trading
Innovative way of bridging the gap between Industry and service
providers through Market based Advisory Councils.
Partnership with leading Utilities domain and market experts in
Europe to bring the Industry best practices and IT services
together. http://www.ucpartners.eu/
Energy and Utilities practice specializes in providing cutting edge
technology solutions in Automatic Meter Management (AMM), Asset
and Work Management , Energy Trading, Balancing Mechanism,
Field Force Automation, SOA based Energy Trading framework to
implement flexibility, re-usability and competitive strategy and
Integration of systems and processes to get STP.
Manufacturing
Globally manufacturing companies are undergoing a change. With
rising customer expectations and increasing competition generating
pressure on margins, companies are being pushed to innovate on new
products and services with increased operational complexity.
Companies cannot be run in the traditional way anymore. In this
competitive market only whose who control costs , invest on product
innovation and reduce time to market will surge ahead.
We believe that IT can be an enabler to create the culture change to
drive companies in that direction. We leverage on our range of
solutions and services to engage with the customer to be a true
'Transformation Partner'.
51
http://www.ucpartners.eu/http://www.ucpartners.eu/ -
8/3/2019 Project Report on Zensar Pharma
52/88
With 200+ experienced consultants in different streams have engaged
in 50 over projects of diverse complexities. Our engagement ranges
from many fortune 500 companies engaged with us for long periods
upto 8-10 years which is deep and matured and also includes SMEs for
quick short cycle implementations as well.
We deliver enterprise class solution core to manufacturing and supply
chain and around all related services which are extremely critical to
make an IT enablement most effective as an end to end partner.
Consulting Services (Consulting Practice)
To help device IT enablement strategy based on organization's IT readiness
and future growth plans so IT can be used as true business transformation
tool.
Oracle ERP - Manufacturing and Supply Chain Implementation
SAP - Implementation Solution in manufacturing and supply chain
space
Product Development
Manufacturing Operations
Demand Driven Supply Chain - Demantra
Supply Chain Management
Reverse Logistics - Service Supply Chain
Business intelligence / Enterprise performance Management
In manufacturing and supply chain space
Customer Operations
52
http://www.zensar.com/industries_Oracle.htmlhttp://www.zensar.com/industries_SupplyChain.htmlhttp://www.zensar.com/industries_SupplyChain.htmlhttp://www.zensar.com/industries_ProductDevelopment.htmlhttp://www.zensar.com/industries_ManufacturingOperations.htmlhttp://www.zensar.com/industries_DemandSupply.htmlhttp://www.zensar.com/industries_SupplyChain.htmlhttp://www.zensar.com/industries_ReverseLogistics.htmlhttp://www.zensar.com/industries_BusinessIntelligence.htmlhttp://www.zensar.com/BPO_CustomerInteraction.htmlhttp://www.zensar.com/industries_Oracle.htmlhttp://www.zensar.com/industries_SupplyChain.htmlhttp://www.zensar.com/industries_SupplyChain.htmlhttp://www.zensar.com/industries_ProductDevelopment.htmlhttp://www.zensar.com/industries_ManufacturingOperations.htmlhttp://www.zensar.com/industries_DemandSupply.htmlhttp://www.zensar.com/industries_SupplyChain.htmlhttp://www.zensar.com/industries_ReverseLogistics.htmlhttp://www.zensar.com/industries_BusinessIntelligence.htmlhttp://www.zensar.com/BPO_CustomerInteraction.html -
8/3/2019 Project Report on Zensar Pharma
53/88
Improving customer experience in B2B , B2C and B2E mode by deploying
internal and external portals
Supply Chain Integrations
SOA and EAM - The initial pitch should be a business pitch without too
much technology.
BPO service in Supply Chain
Healthcare and Life Sciences
The healthcare and life sciences industry is seeing a rapid change across the
globe due to evolving research programs, technology advancement and
upcoming business models and frameworks. The entire gamut of the
healthcare & life sciences sector has become very data intensive, owing to
the mandatory and stringent regulatory enforcements leading to multiple
challenges in terms of providing more affordable treatment and better patient
care. The pressure to maintain huge volumes of data and the importance to
ensure accuracy and reliability of the data repository requires companies to
utilize technology in order to address the increasing demand of the industry.
Zensar Technologies helps healthcare and life sciences organizations to
increase operational efficiencies, reduce administrative and delivery cost,
and enhance patient health and wellness through patient-centric processes
and inter-operable methods.
Interoperability is the key between various service offerings. Through proven
technologies, industry best practices, and global delivery capabilities, we
provide high-quality healthcare and life sciences support solutions. By
53
http://www.zensar.com/industries_SupplyChain.htmlhttp://www.zensar.com/BPO_KPO.htmlhttp://www.zensar.com/industries_SupplyChain.htmlhttp://www.zensar.com/BPO_KPO.html -
8/3/2019 Project Report on Zensar Pharma
54/88
leveraging our experience, we have developed technical expertise in
providing services like data integration and warehousing, business
intelligence and enterprise collaboration solutions, domain-specific
frameworks and business models, process outsourcing and many more.
Life Sciences
We help in structuring yourprocesses as you embark on your success story
of innovation from Molecule to Market.
Share our expertise - Our industry experts continuously keep an eye on
the industry standards & government regulations
Leverage our experience Our years of experience can prove to be
immensely beneficial in optimizing the lead times by accelerating the
product release process
Trust our confidence We have become proficient in understanding
the support requirements in the drug development processes, and thus
offer customized services for workflow management, tracking &
traceability, innovative marketing and design packages
54
-
8/3/2019 Project Report on Zensar Pharma
55/88
INSURANCE
Insurance
In today's scenario, Insurers face issues like globalization, growing demand
for web based services, regulatory demands, security threats and outsourcing.
We understand the needs of the industry and offer Innovative Solutions
which are unique, optimal and customer focused. Through a unique blend of
domain knowledge, technology and robust processes we have successfully
provided solutions to our leading Insurance Customers who faced challenges
like
Demanding business need for new, innovative applications in the
shortest possible time
Striking balance between new technology adoption and the legacy
environments
Long term plan for Application Integration, re-engineering and
retirement
Application and infrastructure maintenance
Availability of skilled resources
Managing dynamic regulatory compliances in the legacy environment
55
http://www.zensar.com/insurancehttp://www.zensar.com/insurance -
8/3/2019 Project Report on Zensar Pharma
56/88
Service Offerings
We provide end-to-end IT services and solutions helping insurers in achieve
operational excellence, exceed customer expectations, faster time-to-market,
while driving their top-line revenue growth.
Banking
Banking and Financial Services Practice at Zensar is built on the strength of
four core competencies - Domain, Process, Technology and Innovation. The
practice is boosted by a myriad of activities like industry research and trends,
tools evaluation, continuous process optimization, innovation leading to
intellectual property, publishing white papers and capturing experiences in
the form of best practices and case studies.
Zensar's Banking and Financial Services Practice addresses the needs of
clients by leveraging its rich industry experience and deep technology
expertise. Our highly qualified team engages with clients to help them
implement sustainable business strategies while maintaining cost efficienciesand thereby, gain competitive advantage in their marketplaces. Through a
network of alliances and partnerships, we provide true end-to-end business
transformation services to our clients.
Energy and Utilities
Energy and Utilities
Energy and Utilities
Energy and Utilities (E & U) practice of Zensar possesses deep domain
expertise and exposure to Global Utility markets backed by 15 years of
hands on experience in the Industry's core technologies. E & U practice has
56
-
8/3/2019 Project Report on Zensar Pharma
57/88
participated in the regulation and deregulation journey of the energy markets
and is actively assisting customers in achieving their goals and objectives.
E & U practice has acquired, expertise in the entire value chain of Energy &
Utilities industry's upstream, mid-stream, down-stream sectors and back
office operations with cumulative experience of 150+ projects and
over15000+ person years.
Upstream
Transmission Outage and Generation Availability,
Asset Management and Maintenance
Inventory Control
Fuel management
Midstream
Network Analysis, MIMS
Balancing Mechanism
Integrated Energy Management BETTA
Mains Risk Priority Management
SCADA
GIS
Downstream
Emergency Meter Work Job Issue System
Demand Derivation system
Field Force Device Replacement,
Connections work management & AMR,
57
-
8/3/2019 Project Report on Zensar Pharma
58/88
Market Intelligence & Provision of Information
Back Office Operations
Knowledge Management
Enterprise Collaboration
EUC Applications
Infrastructure Management
ERP
58
-
8/3/2019 Project Report on Zensar Pharma
59/88
MANUFACTURING
Manufacturing
Globally manufacturing companies are undergoing a change. With rising
customer expectations and increasing competition generating pressure on
margins, companies are being pushed to innovate on new products and
services with increased operational complexity. Companies cannot be run in
the traditional way anymore. In this competitive market only whose who
control costs , invest on product innovation and reduce time to market will
surge ahead.
We believe that IT can be an enabler to create the culture change to drive
companies in that direction. We leverage on our range of solutions and
services to engage with the customer to be a true 'Transformation Partner'.
With 200+ experienced consultants in different streams have engaged in 50
over projects of diverse complexities. Our engagement ranges from manyfortune 500 companies engaged with us for long periods upto 8-10 years
which is deep and matured and also includes SMEs for quick short cycle
implementations as well.
We deliver enterprise class solution core to manufacturing and supply chain
and around all related services which are extremely critical to make an IT
enablement most effective as an end to end partner.
SAP
Zensar offers innovative and cost effective Manufacturing solutions in SAP.
The pre-configured industry solution mySAP All-in-One for the
59
-
8/3/2019 Project Report on Zensar Pharma
60/88
Manufacturing Industry, addresses typical business challenges prevailing in
this segment. A more focused pre-configured offering OBTEngg is an
integrated solution that covers complete business processes needs of the
Manufacturing industry like Machine Building, Fabrication, Component
Manufacturing OEM, Component Manufacturing Replacements and Design
and Development. Both these solution has enable us to offer high quality
solution at affordable costs on a fixed time and cost basis. As a one-stop SAP
Solution Provider, ZensarOBT offers turnkey solution consisting of SAP
Licenses, Computer Hardware, Implementation, and Annual Maintenance to
all its clientele.
OBTEngg, offers comprehensive business functionalities with a ready-to-use
reporting system, which also complies with regulatory principles. The
solution can be implemented in little over 75 days, which means Faster
Return on Investment. OBTEngg reduces the implementation time drastically
while maintaining all the required functionality. Typical features of this
product include:
Integrated Solution for Design, Pilot launch and stabilization.
Variant configuration to facilitate complex product manufacturing.
Complete solution of contract manufacturing.
Quality assurance and monitoring based on customer and Vendor
specific quality plans.
SPC monitoring for process improvements.
On-line OEE and NEE calculation for quick and effective feedback for
the management to take necessary improvement measures.
60
-
8/3/2019 Project Report on Zensar Pharma
61/88
Preventive and Break down maintenance of machineries and
Production resource tools.
Effective solutions with Document management system coupled with
Manufacturing change management for Monitoring design changes.
Export management system with all the statutory documents required.
Business Intelligence
The Manufacturing world's most critical need is the ability to get a single
enterprise view of end to end enterprise information from vendors/ suppliers
to customers in order to fuel the realization of investments made in
information technology. Our BIDW practice provides custom-made solutions
for the manufacturing industry, with a special focus on High Tech, Consumer
Electronics and Traditional Manufacturing corporations. Having provided
end-to-end BI solutions for several Global Manufacturing Conglomerates,
we have developed the expertise required to help Manufacturing companies
achieve performance excellence in an increasingly challenging and complex
industry scenario.Our solutions for this sector encompass every mission critical function that
needs monitoring to improve the overall profitability of the Manufacturing
Organisation. These industry centric solutions, along with our Strategic
Business Intelligence Framework provide the BI Excellence, which is the
key to Enterprise Performance Management. Zensar's Business Intelligence
& Data Warehousing Solutions for the Manufacturing Industry include,
Inbound Logistics, Planning and Production, Sales and Marketing,Finance,
Human Resources and After Sales Services.
61
-
8/3/2019 Project Report on Zensar Pharma
62/88
Over The Counter Products
India continues to hold a significant pharmaceutical market potential, not
least due to its large and rapidly expanding population. Prescription drugs
account for around two-thirds of the total market, with over-the-counter
(OTC) products likely to benefit from the liberalisation of retail channels
anticipated during the forecast period. Generics represent less than 40% of
the market by value, although intellectual property (IP) regime shortcomings
allow for the production and use of counterfeit drugs. India's imports of
medicines are expected to overtake its exports, resulting in a trade deficit of
US$300mn by 2010, although foreign acquisitions by large domestic generic
manufacturers will boost exports of cheaper drugs. The Indian drug sector
remains highly competitive, with the state pricing policy continuing to stifle
growth and the new drug patent law set to increase foreign company activity.
BMI expects the pharmaceutical sector to grow by some 8% in 2006, behind
the country's major Asian rival, China. Sales are likely to exceed US$15.2bn
by 2010, with annual growth at around 9%. The growth of 'civilisation'
diseases, boosted by changing demographics and rising healthcare
expectations, will simulate the need for cardiovascular, neurological,
metabolic and cancer drugs in particular. The treatment of infective diseases,
especially hepatitis and HIV/AIDS, will necessitate supplies from abroad,
while simultaneously encouraging local research and development (R&D)
activities in this direction. Expected liberalisation of over-the-counter (OTC)
medicine sales channels will in the short term result in shrinking profits, but
in the longer term boost the sector's performance. However, the expected
62
-
8/3/2019 Project Report on Zensar Pharma
63/88
price cuts will have a significant negative effect on all sectors of the industry
and its commitment to local R&D and future launches, while potentially
boosting trade in counterfeits.
In regional terms, India will outperform a number of its neighbours, boosted
by its ongoing industrial development, foreign direct investment and
overseas activities. However, IP and pricing problems will continue to hinder
pharmaceutical sector growth over the coming years. Indeed, the government
is planning to reduce the prices of approximately 8% of all drugs sold in the
country, with the most expensive treatments receiving the largest cuts.
Nevertheless, BMI's adjusted Business Environment Rankings for Asia place
India in sixth place, behind China.
Indian firms continue to expand in advanced markets, both through outright
acquisitions of overseas facilities and generic product approvals in advanced
markets. Most recently, Venus Remedies has secured a deal to export its
oncology products to Ukraine. International companies remain interested in
the Indian market, which is developing due to population growth, as well as
improvements in economic conditions and patent law. Consequently, new
launches will become a more frequent occurrence. US-based Bristol-Myers
Squibb has recently introduced Baraclude to meet the rising, but as yet
unmet, medical need for chronic hepatitis B treatment in India.
Countries covered: India
India continues to hold a significant pharmaceutical market potential, not
least due to its large and rapidly expanding population. Prescription drugs
account for around two-thirds of the total market, with over-thecounter
(OTC) products likely to benefit from the liberalisation of retail channels
63
-
8/3/2019 Project Report on Zensar Pharma
64/88
anticipated during the forecast period. Generics represent less than 40% of
the market by value, although intellectual property (IP) regime shortcomings
allow for the production and use of counterfeit drugs. Indias imports of
medicines are expected to overtake its exports, resulting in a trade deficit of
US$300mn by 2010, although foreign acquisitions by large domestic generic
manufacturers will boost exports of cheaper drugs. The Indian drug sector
remains highly competitive, with the state pricing policy continuing to stifle
growth and the new drug patent law set to increase foreign company activity.
BMI expects the pharmaceutical sector to grow by some 8% in 2006, behind
the countrys major Asian rival, China. Sales are likely to exceed US$15.2bn
by 2010, with annual growth at around 9%. The growth of civilisation
diseases, boosted by changing demographics and rising healthcare
expectations, will simulate the need for cardiovascular, neurological,
metabolic and cancer drugs in particular. The treatment of infective diseases,
especially hepatitis and HIV/AIDS, will necessitate supplies from abroad,
while simultaneously encouraging local research and development (R&D)
activities in this direction. Expected liberalisation of over-the-counter (OTC)
medicine sales channels will in the short term result in shrinking profits, but
in the longer term boost the sectors performance. However, the expected
price cuts will have a significant negative effect on all sectors of the industry
and its commitment to local R&D and future launches, while potentially
boosting trade in counterfeits.
In regional terms, India will outperform a number of its neighbours, boosted
by its ongoing industrial development, foreign direct investment and
64
-
8/3/2019 Project Report on Zensar Pharma
65/88
overseas activities. However, IP and pricing problems will continue to hinder
pharmaceutical sector growth over the coming years. Indeed, the government
is planning to reduce the prices of approximately 8% of all drugs sold in the
country, with the most expensive treatments receiving the largest cuts.
Nevertheless, BMIs adjusted Business Environment Rankings for Asia place
India in sixth place, behind China.
Indian firms continue to expand in advanced markets, both through outright
acquisitions of overseas facilities and generic product approvals in advanced
markets. Most recently, Venus Remedies has secured a deal to export its
oncology products to Ukraine. International companies remain interested in
the Indian market, which is developing due to population growth, as well as
improvements in economic conditions and patent law. Consequently, new
launches will become a more frequent occurrence. US based Bristol-Myers
Squibb has recently introduced Baraclude to meet the rising, but as yet
unmet, medical need for chronic hepatitis B treatment in India
Ranbaxy Q1 2007 Net Profit Rises 79% to Rs.129 Crores
Operating profit before tax doubles (Rs 1,597 Mn, up 100%); Consolidated
Revenues at Rs.15,644 Mn; up 23% compared to corresponding quarter.
65
-
8/3/2019 Project Report on Zensar Pharma
66/88
Generic: Amlodipine
VAMLO Ranbaxy Global Consumer Healthcare
Tablet 2.5 mg 10 Rs: 12.45
Tablet 5 mg 10 Rs: 17.95
Tablet 10 mg 10 Rs: 34.35
Generic: Amlodipine + Losartan Potassium
COVAMLO Ranbaxy Global Consumer Healthcare
Tablet 10 Rs: 67.5
Generic: Aspirin (Low Dose)
ASPENT Ranbaxy Global Consumer Healthcare
Tablet 60 mg 14 Rs: 9
Generic: Atorvastatin
STORVAS Ranbaxy Global Consumer Healthcare
Tablet 10 mg 10 Rs: 75
Tablet 20 mg 10 Rs: 140
Tablet 5 mg 10 Rs: 39
Generic: Candesartan
CANDESAR Ranbaxy Global Consumer Healthcare
Tablet 4 mg 10 Rs: 27
Tablet 8 mg 10 Rs: 48
Tablet 16 mg 10 Rs: 80
Generic: Carvedilol
CASLOT Ranbaxy Global Consumer Healthcare
Tablet 12.5 mg 10 Rs: 30
Tablet 3.125 mg 10 Rs: 9
Tablet 6.25 mg 10 Rs: 16
Tablet 25 mg 10 Rs: 52
Tablet 25 mg 10 Rs: 52
Generic: Celiprolol
66
-
8/3/2019 Project Report on Zensar Pharma
67/88
CELIPRES Ranbaxy Global Consumer Healthcare
Tablet 100 mg 10 Rs: 27.7
Tablet 200 mg 10 Rs: 51.15
Generic: Clopidogrel
CERUVIN Ranbaxy Global Consumer Healthcare
Tablet 75 mg 10 Rs: 57.6
Generic: Dextromethorphan
CHERICOF LOZENGES Ranbaxy Global Consumer Healthcare
Lozenges 5 mg 8 Rs: 21
Generic: Esomeprazole
RACIPER Ranbaxy Global Consumer Healthcare
Tablet 20 mg 10 Rs: 21.9
Tablet 40 mg 10 Rs: 37.9
Generic: Fenofibrate
STANLIP Ranbaxy Global Consumer Healthcare
Tablet 160 mg 10 Rs: 70
Generic: Finasteride
FINARA Ranbaxy Global Consumer Healthcare
Tablet 5 mg 5 Rs: 95.4
Generic: GlimepirideGLIMPID Ranbaxy Global Consumer Healthcare
Tablet 1 mg 10 Rs: 53
Tablet 2 mg 10 Rs: 82
Tablet 4 mg 10 Rs: 103.4
Generic: Losartan Potassium
COVANCE Ranbaxy Global Consumer Healthcare
Tablet 25 mg 10 Rs: 26
Tablet 50 mg 10 Rs: 49
67
-
8/3/2019 Project Report on Zensar Pharma
68/88
Generic: Losartan Potassium + Hydrochlorothiazide
COVANCE-D Ranbaxy Global Consumer Healthcare
Tablet 10 Rs: 57
Generic: Metformin
RIOMET OD Ranbaxy Global Consumer Healthcare
Tablet 500 mg 10 Rs: 13
Tablet 1000 mg 10 Rs: 25
Generic: Montelukast
ROMILAST Ranbaxy Global Consumer Healthcare
Tablet 4 mg 10 Rs: 79.3
Tablet 5 mg 10 Rs: 98.8
Tablet 10 mg 10 Rs: 149.95
ROMILAST GRANULES Ranbaxy Global Consumer Healthcare
Sachet 4 mg 1 Rs: 5.85
Generic:Montelukast +
Bambuterol
ROMILAST-B Ranbaxy Global Consumer Healthcare
Tablet 10 Rs: 69
Tablet 10 Rs: 104.6
Generic: PioglitazonePIOGLAR Ranbaxy Global Consumer Healthcare
Tablet 15 mg 10 Rs: 50
Tablet 30 mg 10 Rs: 80
Generic: Quetiapine Fumarate
SOCALM Ranbaxy Global Consumer Healthcare
Tablet 25 mg 10 Rs: 17
Tablet 100 mg 10 Rs: 45
Tablet 200 mg 10 Rs: 85
68
-
8/3/2019 Project Report on Zensar Pharma
69/88
Generic: Rabies Immunoglobulin
IMOGAM RABIES Ranbaxy Global Consumer Healthcare
Vial 300 i.u. 2ml Rs: 3900
Generic: Rabies Vaccine
VERORAB Ranbaxy Global Consumer Healthcare
Vial 0.5ml Rs: 304
Generic: Ramipril
CORPRIL Ranbaxy Global Consumer Healthcare
Capsule 1.25 mg 10 Rs: 15
Capsule 2.5 mg 10 Rs: 40
Capsule 5 mg 10 Rs: 56.9
Generic: Ramipril + Amlodipine
CORPRIL AM Ranbaxy Global Consumer Healthcare
Tablet 10 Rs: 45
Generic: Simvastatin + Nicotinic acid
SIMVOTIN Ranbaxy Global Consumer Healthcare
Tablet 5 mg 10 Rs: 59
Tablet 10 mg 10 Rs: 86
Tablet 20 mg 10 Rs: 141
Generic: Tadalafil
FORZEST Ranbaxy Global Consumer Healthcare
Tablet 10 mg 4 Rs: 78
Tablet 20 mg 4 Rs: 118
Generic: Tolterodine Tartarate
ROLITEN Ranbaxy Global Consumer Healthcare
Tablet 1 mg 10 Rs: 35
Tablet 2 mg 10 Rs: 65
Generic: Valsartan
69
-
8/3/2019 Project Report on Zensar Pharma
70/88
STARVAL Ranbaxy Global Consumer Healthcare
Capsule 80 mg 10 Rs: 69
Capsule 160 mg 10 Rs: 130
70
-
8/3/2019 Project Report on Zensar Pharma
71/88
RESEARCH METHODOLOGY
Sample - Size = 100 Questionnaire
Target Group -
SEC ABCDE
Age Group : 21 + years
Male and female
Users of Zensar and competition brands
Non users of category
Minimum quotas will be ensured for
- Zensar users
- Consumers who have seen Zensar advertising
1. Research Design:
A research design is a pattern or an outline of a research projects working. It is a
statement of only the essential elements of a study, those that provide the basic guidelines
for the details of the project. It comprises a series of prior decision that taken together
provide master plans for executing a research projects.A research design serves as a bridge between what ha